Our Company

Genomenon is an AI-driven genetic intelligence company on a mission to save and improve lives by making biomedical information actionable. Rare diseases and cancer affect more than 30 million people in the U.S. alone and hundreds of millions globally, yet most patients still face long diagnostic journeys and limited treatment options. Our goal is clear and ambitious: to deliver the information that shapes diagnosis and treatment for every rare disease and cancer patient.

We sit at the intersection of AI, genomics, and real world evidence. Genomenon transforms the global scientific literature into a literature derived, real world evidence (RWE) engine for precision medicine—combining large-scale AI with expert human curation to deliver clean, clinically actionable datasets. This approach fills critical gaps left by EHR and claims data, especially in rare disease and oncology, by showing how patients actually present, progress, and respond to therapy.

We turn vast, complex biomedical data—spanning genomics, clinical evidence, and scientific literature—into trusted intelligence that helps clinicians make better diagnostic and therapeutic decisions, and supports life sciences organizations in bringing better therapies to market faster.

Our work has real, measurable impact. Genomenon’s platforms and services are used by more than 250 clinical laboratories and pharma organizations worldwide to support diagnostic interpretation, variant curation, and evidence-based decision-making across the drug development lifecycle. 

Each year, our technology helps inform care for tens of thousands of patients facing rare, complex, and time-sensitive conditions—reducing uncertainty and delivering answers when they matter most.

What makes Genomenon unique is our ability to support both clinical diagnostics and pharmaceutical innovation on a shared foundation of advanced AI, deep domain expertise, and rigorously curated data.

• In the clinic, our solutions directly influence real world patient outcomes.

• In pharma, we enable teams to harness literature derived RWE across clinical trial development, regulatory, and commercial workflows—turning fragmented biomedical knowledge into a strategic asset and emerging as the trusted data layer for genomic diagnostics and precision therapeutics.

If you’re motivated by impact, energized by complexity, and excited to help shape the future of rare disease diagnosis and treatment, there’s no better place to do that work.

Genomenon /ge.gno.mai.non/

Source language: ancient Greek

1. Verb
   to come into being
   to be born out of need